Results 281 to 290 of about 37,820 (304)

Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial

Lancet, The, 2022
Leonard Benjamin Bacharier, Agustin Calatroni, George T O'connor   +2 more
exaly  

Role of Eosinophil Mitochondrial Function in Severe Eosinophilic Asthma

A101. LINKING BIOLOGY TO THE REAL WORLD IN ASTHMA AND ALLERGIC INFLAMMATION, 2023
J.B. Koranteng, S.L. Lai, K.L. Raby, P. Dixey, K.F. Chung, C. Michaeloudes, P.K. Bhavsar   +6 more
openaire   +1 more source

The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study

Lancet Respiratory Medicine,the, 2021
Rekha Chaudhuri, Ian D Pavord, John Busby   +2 more
exaly  

Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma

Chest, 2021
David J Jackson, Jaideep Dhariwal, Grainne d'Ancona   +2 more
exaly  

Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study

Lancet Respiratory Medicine,the, 2022
Andrew Menzies-Gow, Mark Gurnell, Liam G Heaney   +2 more
exaly  

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

Lancet, The, 2012
Ian D Pavord, Peter Howarth, Eugene R Bleecker   +2 more
exaly  

Mepolizumab for severe eosinophilic asthma

Expert Review of Respiratory Medicine
Maria Kallieri, Andriana I. Papaioannou, Stelios Loukides   +2 more
openaire   +1 more source

Lysis of primed eosinophils in severe asthma

Journal of Allergy and Clinical Immunology, 2013
openaire   +2 more sources

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

Lancet, The, 2016
J Mark Fitzgerald, Eugene R Bleecker, Parameswaran Nair   +2 more
exaly  

Treatment for severe eosinophilic asthma—consistent effect of anti-interleukin-5 antibodies?

Lancet, The, 2016
Mario Castro, Leonard Benjamin Bacharier
exaly